Table 2. Comparison of changes in clinical parameters and anemia therapy prescription patterns between baseline and SO 1 – 3 for patients with 1 – 3 months of SO follow-up (n = 1,029).
| Parameter | Baseline | SO 1 – 3 | p-value |
|---|---|---|---|
| Pill burden | |||
| Prescribed PB pills/day | 9.6 ± 4.3 | 3.8 ± 1.3 | < 0.001 |
| MBD markers | |||
| Patients with serum phosphorus ≤ 5.5 mg/dL, n (%) | 143 (13.9) | 269 (26.1) | < 0.001 |
| Serum phosphorus, mg/dL | 6.93 ± 1.39 | 6.65 ± 1.61 | < 0.001 |
| Serum calcium, mg/dL | 9.24 ± 0.69 | 9.19 ± 0.72 | 0.002 |
| iPTH, pg/ml | 578.1 ± 479.8 | 598.4 ± 506.2 | 0.06 |
| Clearance and nutritional parameters | |||
| Albumin, g/dL | 3.96 ± 0.31 | 3.96 ± 0.31 | 0.8 |
| enPCR, g/kg/day | 0.97 ± 0.21 | 0.95 ± 0.21 | 0.001 |
| eKT/V | 1.46 ± 0.22 | 1.46 ± 0.23 | 0.6 |
| Patients receiving IV iron therapy (n = 895)a | |||
| Iron indices | |||
| Ferritin, ng/mL | 986.0 ± 484.3 | 1014.3 ± 478.1 | 0.1 |
| TSAT, % | 34.1 ± 10.4 | 35.5 ± 12.3 | 0.001 |
| Hemoglobin, g/dL | 10.9 ± 1.0 | 10.9 ± 1.1 | 0.9 |
| Anemia therapy medications | |||
| IV iron use, n (%)a | 810 (90.5) | 720 (80.4) | < 0.001 |
| Iron sucrose use, n (%) | 808 (99.8) | 718 (99.7) | < 0.001 |
| Iron sucrose dose, mg/week | 66.9 ± 42.9 | 71.0 ± 57.1 | 0.1 |
| ESA use, n (%)b | 773 (86.4) | 738 (82.5) | < 0.001 |
| Epoetin-α use, n (%) | 735 (95.1) | 679 (92) | < 0.001 |
| Epoetin-α dose, U/HD Tx | 3560 ± 3288 | 3534 ± 3608 | 0.8 |
| Epoetin-α dose, U/administration | 5225 ± 4322 | 4957 ± 4315 | 0.01 |
| Patients not receiving IV iron therapy (n = 134)a | |||
| Iron indices | |||
| Ferritin, ng/mL | 1151.9 ± 597.5 | 1113.1 ± 842.2 | 0.6 |
| TSAT, % | 38.0 ± 15.0 | 35.9 ± 15.2 | 0.06 |
| Hemoglobin, g/dL | 11.2 ± 1.5 | 11.2 ± 1.6 | 0.9 |
| Anemia therapy medications | |||
| ESA use, n (%)b | 97 (72.4) | 88 (65.7) | 0.007 |
| Epoetin-α use, n (%) | 93 (95.9) | 82 (93.2) | 0.002 |
| Epoetin-α dose, U/HD Tx | 3389 ± 3411 | 3382 ± 3454 | 0.9 |
| Epoetin-α dose, U/administration | 5074 ± 4358 | 4892 ± 4462 | 0.5 |
Values are expressed as mean ± SD or number (%) of patients; aIV iron treatment includes iron sucrose, ferumoxytol, and sodium ferric gluconate; bESA treatment includes epoetin-α, epoetin-β, and methoxy polyethylene glycol, and darbepoetin-α; ESA= erythropoiesis stimulating agent; iPTH = intact parathyroid hormone; IV = intravenous; MBD = mineral bone disease; PB = phosphate binder; enPCR = equilibrated normalized protein catabolic rate; SD = standard deviation; SO = sucroferric oxyhydroxide; TSAT = transferrin saturation; Tx = treatment.